Table 1_Real-world effectiveness of first-line immunotherapy with or without chemotherapy

A retrospective study of 401 patients with stage IV non-small cell lung cancer treated at Shanxi Province Cancer Hospital between January 2019 and December 2021. It compares overall survival between chemotherapy alone and immunotherapy with or without chemotherapy, and explores outcomes for domestically versus internationally developed PD-1 inhibitors. The data was collected and analyzed by Lihua Li.

Use Cases

• Compare overall survival outcomes based on first-line treatment regimen (immunotherapy with/without chemotherapy vs. chemotherapy alone).
• Analyze survival associations with patient factors like BMI, smoking status, and pre-existing pulmonary disease.
• Evaluate the impact of concomitant medication use (corticosteroids, antibiotics, proton pump inhibitors) on patient survival.
• Compare the effectiveness of domestically developed PD-1 inhibitors (camrelizumab, sintilimab, tislelizumab) versus the internationally developed pembrolizumab.

Strengths

• Includes data from 401 patients, providing a substantial real-world cohort.
• Reports specific median overall survival figures (22.0 months vs. 14.0 months) with statistical significance.
• Conducts subgroup analyses based on BMI, smoking status, T stage, and medication use.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The study notes limited sample sizes within some subgroups, requiring cautious interpretation of those findings.

Provenance

Source

Shanxi Province Cancer Hospital

Collection Method

Retrospective data collection from patient records.

Time Range

January 2019 to December 2021

Freshness

Last updated 2026-05-12 05:42:47; freshness should be verified.

Geography

China (Shanxi Province)